Illustration: Sarah Grillo/Axios
ArisGlobal, a sponsor-backed AI drug development software company, has lost out on two prospective acquisitions.
Why it matters: ArisGlobal appears to be trying to address the SaaSpocalypse by building out its agentic platform.
